Lupin Launches Topiramate Extended-Release Capsules in the United States [Yahoo! Finance]
Supernus Pharmaceuticals, Inc. (SUPN)
Last supernus pharmaceuticals, inc. earnings: 2/25 04:40 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.supernus.com
Company Research
Source: Yahoo! Finance
announced the launch of Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, and 200 mg, in the United States, following the approval for its Abbreviated New Drug Application (ANDA) from the U.S. FDA. Topiramate Extended-Release Capsules are bioequivalent to the reference listed drug (RLD), Trokendi XR® Extended-Release Capsules of Supernus Pharmaceuticals, Inc. (Supernus). It is indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 6 years of age and older, as adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome in patients 6 years of age and older, and for the preventive treatment of migraine in patients 12 years of age and older. Topiramate Extended-Release Capsules has an estimated annual sale of USD 164 million in the U.S. (IQVIA MAT Dec 2025). About Lupin Lupin Limited is a global pharmaceut
Show less
Read more
Impact Snapshot
Event Time:
SUPN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SUPN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SUPN alerts
High impacting Supernus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SUPN
News
- Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
- Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SUPN&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">WalMarketBeat
- 2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds [Yahoo! Finance]Yahoo! Finance
- Is Supernus Pharmaceuticals (SUPN) Still Attractive After Strong Multi-Year Share Price Gains [Yahoo! Finance]Yahoo! Finance
- 3 Low-Volatility Stocks We're Skeptical Of [Yahoo! Finance]Yahoo! Finance
SUPN
Earnings
- 11/4/25 - Miss
SUPN
Analyst Actions
- 12/19/25 - Stifel
SUPN
Sec Filings
- 2/2/26 - Form SCHEDULE
- 1/28/26 - Form 8-K
- 1/21/26 - Form SCHEDULE
- SUPN's page on the SEC website